Stefan Galluppi Sells 85,000 Shares of LifeMD, Inc. (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD) insider Stefan Galluppi sold 85,000 shares of LifeMD stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $12.38, for a total value of $1,052,300.00. Following the completion of the transaction, the insider now owns 80,449 shares in the company, valued at $995,958.62. The trade was a 51.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

LifeMD Trading Up 10.9%

LFMD stock opened at $15.06 on Thursday. LifeMD, Inc. has a 1-year low of $3.99 and a 1-year high of $15.29. The firm has a market cap of $684.48 million, a P/E ratio of -44.29 and a beta of 2.42. The business’s 50 day moving average is $9.38 and its 200-day moving average is $6.89.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.05. The company had revenue of $65.70 million during the quarter, compared to the consensus estimate of $62.47 million. Sell-side analysts forecast that LifeMD, Inc. will post -0.56 EPS for the current year.

Institutional Investors Weigh In On LifeMD

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC bought a new stake in shares of LifeMD in the 1st quarter valued at approximately $35,000. CWM LLC increased its holdings in LifeMD by 17.5% during the 1st quarter. CWM LLC now owns 9,050 shares of the company’s stock valued at $49,000 after purchasing an additional 1,351 shares in the last quarter. ProShare Advisors LLC acquired a new stake in LifeMD during the 4th quarter valued at $51,000. Oxford Asset Management LLP acquired a new stake in LifeMD during the 4th quarter valued at $52,000. Finally, Balyasny Asset Management L.P. acquired a new stake in LifeMD during the 4th quarter valued at $52,000. 35.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on LFMD shares. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of LifeMD in a research note on Wednesday, April 30th. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price target on shares of LifeMD in a research note on Tuesday, March 11th. B. Riley upgraded LifeMD to a “strong-buy” rating in a research note on Tuesday, March 11th. Finally, BTIG Research boosted their price target on LifeMD from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $12.00.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.